Last reviewed · How we verify
NCT06880029: CIRCADIAN
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
Phase 1, PHASE2 trial testing Morning pembrolizumab infusions in Triple Negative Breast Cancer (TNBC) in 20 participants. Currently enrolling.
1 September 2025
Quick facts
| Lead sponsor | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 September 2024 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across Portugal |
Drugs / interventions tested
- Morning pembrolizumab infusions
Conditions studied
- Triple Negative Breast Cancer (TNBC) — all drugs for Triple Negative Breast Cancer (TNBC) →
Sponsor
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Who can join
Adults 18 to 75, female only, with Triple Negative Breast Cancer (TNBC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06880029
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Triple Negative Breast Cancer (TNBC)
Currently open trials in the same condition.
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
- NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · Phase 2 · recruiting
- NCT07342283 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer · Phase 2 · recruiting
- NCT07182149 — A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · Phase 1 · recruiting
- NCT06606730 — Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer · Phase 3 · recruiting
Other Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. trials
Trials by the same sponsor.
- NCT05692375 — Impact of the Save the Shame! Game on Advanced Life Support Knowledge · NA · completed
- NCT05140057 — Preparation Regimens to Improve Capsule Endoscopy Visualization and Diagnostic Yield · NA · unknown
- NCT04301362 — Biomarkers of Thrombosis as Predictors of Venous Thromboembolism Risk in Cancer Patients · unknown
- NCT04820010 — Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3 · completed
- NCT03280433 — Influence of EPICardial Adipose Tissue in HEART Diseases: EPICHEART Study · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06880029 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
- Last refreshed: 19 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06880029.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing